Dataset from A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Continuation Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (QuANTUM First)

Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research.Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer (FLT3-ITD AML).Participants will have an equal chance of receiving quizartinib or placebo along with their chemotherapy.